Komori
⌘K
by
Hone Systems
Hone
Open
09:00
Loading
Home
Market
Watch
Notifications
All
Threads by company (from 2782) | Komori
Komori
⌘K
by
Hone Systems
Hone
Open
09:00
Recently moved threads
/
Threads by company (from 2782)
Home
Recently moved threads
Threads by company (from 2782)
Threads by company (from 2782)
Every company with threads, and all of its threads, in ticker order.
Home
Market
Watch
Notifications
All
Threads by company
2782
Seria Co.,Ltd.
2026-10-31
Newly added to TOPIX
2026-10-30
Building the Foundation for Sustained Store Expansion
2026-10-30
Plan to Open 144 Stores by March 2017
2026-10-30
Prioritizing Individual Store Profitability and Reviewing Unprofitable Stores
2026-10-30
Developing Attractive Products, Creating Stores That Are Easy to Shop, and Improving Operating Efficiency
2026-10-30
Introducing New Products
2026-10-30
Expanding the Store Network
2026-10-30
Risk of Inventory Growth and Slow-Moving Stock
2026-10-30
Risk of Higher Costs Due to Foreign-Exchange and Commodity-Market Fluctuations
2026-10-30
Impairment Risk for Fixed Assets
2026-10-30
Risk of Store and Logistics-Network Disruptions Due to Natural Disasters or Accidents
2026-10-30
Policy of Maintaining Stable Dividends While Strengthening the Financial Base
2026-10-30
Policy of Reinvesting Retained Earnings in Store Openings and Renovations
2026-10-30
Slowing Overseas Economies, Yen Appreciation and Global Economic Uncertainty
2026-10-30
Year-on-Year Growth in Same-Store Sales at Company-Operated Stores
2026-10-30
Year-on-Year Improvement in the Operating Profit Margin
2026-10-30
Growth in Revenue, Operating Profit, Ordinary Profit and Net Income
2026-10-30
Interest-Rate Risk Associated with Variable-Rate Borrowings
2026-10-30
Increase in Estimated Asset Retirement Obligations Associated with Store Closures
2026-10-30
Changes in Demand Due to Pent-Up Demand and Shifts in Consumer Behavior
2026-06-24
Three-Year Medium-Term Plan and Rolling Approach
2026-06-24
Improving Quality Through New Product Development and Product Enhancements
2026-06-24
Rebuilding the Operating Structure
2026-06-24
Enhancing Core Products
2026-06-24
Transition to a Company with an Audit and Supervisory Committee
2026-06-24
Stable Maintenance of an Operating Profit Margin of at Least 5.0% of Revenue
2026-06-24
Growth in Overseas Revenue and Development of Business Partners
2026-06-24
Strengthening Product Development Through Tokyo and Osaka Satellite Offices
2026-06-24
Risk of Reversing Deferred Tax Assets Due to Changes in Future Taxable Income
2026-06-24
A Diverse and Fair Workplace Where All Employees Can Work and Grow with Confidence
2026-06-24
Maintaining a Female Management Ratio of at Least 30%
2026-06-24
Employment of People with Disabilities at a Statutory Rate of at Least 2.3%
2026-06-24
Promoting Employees from Part-Time Roles and Utilizing Mid-Career Hires
2026-06-24
Disclosure of the Gender Pay Gap
2026-06-24
Disclosure of the Male Employee Parental-Leave Uptake Rate
2026-06-24
Head-Office Relocation Plan
2026-06-24
Reorganization and Closure of Sales Offices
2026-06-24
Diversifying the Board Through the Appointment of a Female Director
2026-06-24
Application of the Accounting Standard for Subsequent Events from the Fiscal Year Ending March 2028
2026-06-02
Prioritizing Quality and Product Range Over Price Competition
2026-06-02
Intensifying Competition in the Retail Industry
2026-06-02
Executive Compensation and Director-Candidate Selection Criteria Focused on Enhancing Corporate Value
2026-06-02
Execution of Directors and Officers Liability Insurance
2026-06-02
Shareholder Returns and Capital Policy Through Share Repurchases
2025-11-10
Improving the Financial Position, Reducing Reliance on Borrowings and Lowering Funding Costs
2025-06-25
Product Introductions and Stockout Prevention Through POS Data Analysis
2025-06-25
Strengthening a Demand-Responsive Supply Chain by Sharing Data-Utilization Practices with Suppliers
2025-06-25
Offering Valuable Products and New Value at ¥100 Based on Cleanliness, Gratitude and Sharing
2025-06-25
Saturation of the ¥100 Shop Market and Potential Decline in Profitability
2025-06-25
Application of the Lease Accounting Standard from the Fiscal Year Ending March 2028
2024-11-08
Sharing Management Issues Internally and Resolving Them Company-Wide
2024-06-20
Operation of the Risk Management and Compliance Committees
2024-06-20
Conducting Self-Audits at Every Store at Least Once a Year
2024-06-20
Sustainability Policy and Promotion Through Management Meetings and the Board of Directors
2024-06-20
Introduction of a Selective Defined-Contribution Pension Plan
2023-08-10
Store Closures and Business Impact from the Spread of COVID-19
2023-06-21
Constraints on Store Openings Under the Large-Scale Retail Stores Location Law and Other Regulations
2023-06-21
Risk of Missing Store-Opening Plans Due to a Shortage of Suitable Properties or Commercial-Facility Closures
2023-06-21
Credit Deterioration and Bad-Debt Risk Among Franchisees
2023-06-21
Establishment and Operation of the Internal Control System
2023-06-21
Information Management Through Document-Control Rules and Network Monitoring
2023-06-21
Excluding Antisocial Forces and Establishing a Code of Conduct and Compliance Guidelines
2023-06-21
Building a Common Understanding of Issues and Sharing Information Through Management Meetings
2022-06-23
Application of accounting standards for fair value measurement
2022-06-23
Transfer to the Tokyo Stock Exchange Standard Market
2021-08-10
Application of the Revenue Recognition Accounting Standard from the Fiscal Year Ending March 2022
2021-06-24
Rebuilding the Operating Platform Through Outsourcing and New Logistics Hubs
2021-06-24
Mitigating Variable-Rate Risk Through Interest-Rate Swaps
2020-06-24
Establishing Seria's Original Chain Operations
2020-06-24
Rebuilding the Profitability Management Framework
2018-11-09
Brand Building as the Backbone of Sustainable Growth
2017-08-10
Lowering the investment unit and improving liquidity through a stock split
2784
Alfresa Holdings Corporation
2026-10-23
Building an Open Health and Medical Platform for Local Communities
2026-10-16
Stable Pharmaceutical Supply During Disasters Through BCP
2026-10-16
ドローン活用による医薬品配送・災害時物資輸送
2026-09-30
Entry into the Animal Healthcare Market and Capital Alliance with Morikubo CA Medical
2026-09-29
Integration and Restructuring of Regional Wholesale Companies
2788
APPLE INTERNATIONAL CO.,LTD.
2026-09-18
Expanding Automotive Distribution in Southeast Asia, Led by Thailand
2026-09-18
Slowing Demand for High-Priced Vehicles in Southeast Asia Due to Rapid Yen Appreciation
2026-09-18
Establishing a Framework for the Early Resumption of Dividends
2026-09-18
Meeting the Forecast for the Next Fiscal Year
2026-09-17
Uncertainty in the External Environment Due to Brexit and China's Economic Slowdown
2789
Karula Co.,LTD.
2026-10-13
Menu initiatives, including the launch of new products
2026-10-13
Cost pressure from rising raw material prices and labor costs
2026-10-13
Concerns over a downturn in emerging-market economies and uncertainty over the economic outlook
2026-10-13
Lower sales and earnings
2026-10-13
Impairment Losses Incurred at Certain Stores
278A
Terra Drone Corporation
2026-10-29
Growing Demand for UTM Security Solutions for Critical Infrastructure
2026-10-21
Policy shifts, regulatory changes and intensifying competition in the drone market
2026-10-21
Full-scale entry into the defense equipment market and global expansion of unmanned assets
2026-10-21
Development of Interceptor Drones, Strategic Investment and Product Lineup Expansion
2026-09-17
Deployment of UTM and Counter-UAS for Critical Infrastructure and Defense Airspace
First page
Next
2026-09-16
Strengthening the Business as One Group
2026-09-16
Strengthening the business foundation as the No. 1 wholesaler of prescription drugs
2026-08-21
Strengthening the Foundation of the Dispensing Pharmacy Business and Expanding into Related Healthcare Fields
2026-08-05
Strengthening the Production System and Strategic Investment
2026-08-05
Investment in a Regenerative Medicine and Gene Therapy Venture
2026-08-05
Realization of Total Supply Chain Services
2026-08-05
Strengthening clinical development, regulatory submissions and post-marketing surveillance capabilities through the acquisition of CRO and PMS businesses
2026-08-03
Strengthening Manufacturing Capabilities in Regenerative Medicine Through the Establishment of セルリソーシズ
2026-08-03
Domestic Biosimilar Manufacturing and CDMO Joint Venture
2026-07-31
Stable Supply, Enhancement of Corporate Value and Contribution to Society Based on the Corporate Philosophy Framework
2026-07-30
Advancing Distribution Reform
2026-07-30
Nationwide Distribution of Orphan Drugs and Specialty Pharmaceuticals
2026-07-30
Risk to stable supply from damage to logistics functions
2026-07-22
Joint development of a retail media business
2026-07-14
Developing People to Take on Uncharted Areas and Adapt to New Environments
2026-07-14
Human resource development and regional engagement through the transfer and establishment of a corporate baseball team
2026-06-24
Corporate Governance That Prioritizes Transparency, Fairness and Prompt Decision-Making
2026-06-24
Strengthening Oversight and Advisory Functions Through Outside Directors
2026-06-24
Group-wide Internal Control and Compliance Framework
2026-06-23
Realizing a Healthcare Consortium
2026-06-23
Product pipeline comprising in-house development, implementation development and joint development
2026-06-23
Enhancing Shareholder Value Through Share Repurchases
2026-06-23
Dividend policy based on a DOE of at least 2%
2026-06-23
Shareholdings to strengthen business relationships
2026-06-23
Risk of Earnings Volatility Due to Healthcare System Reforms and Drug Price Revisions
2026-06-23
Risks of Transactions with Undetermined Prices and Prolonged Price Negotiations
2026-06-23
Risks Related to Product Development, Supply Discontinuation, and Product Safety
2026-06-23
Risks Related to Dispensing Errors and Securing Pharmacists
2026-06-23
Risk of Sales and Logistics Disruption Due to System Outages
2026-06-23
Risk of declines in the market prices of shares held and impairment of investments
2026-06-23
Downside Risks from Domestic and Overseas Economic Conditions, Financial Markets and Personal Consumption
2026-06-23
Business Strengthening and Expansion Investments of Approximately ¥120 Billion Over 3 Years
2026-06-23
Investment in an Online Medical Consultation System Company
2026-06-23
Net-Zero CO2 Emissions by 2050 and Reduction Targets
2026-06-23
Target for increasing the proportion of women in management
2026-06-23
Work-Life Balance and Promoting Men's Use of Childcare Leave
2026-06-23
Disclosure of the Gender Pay Gap for Workers
2026-06-23
Impairment Risk in Capital Expenditures, Venture Investments and M&A Investments
2026-06-23
Alfresa Group's Medium- to Long-Term Vision Through Fiscal 2032
2026-06-23
eNPS Employee Engagement Survey and Improving Response Rates
2026-06-23
Introduction of a Group-wide Talent Management System
2026-06-23
Medium-Term Management Plan for FY2025–FY2027: “Vision2032 Stage 2”
2026-06-23
Target of keeping strategic shareholdings below 10% of consolidated net assets
2026-06-23
¥35.5 billion in capital investment for the fiscal year ending March 2027
2026-06-23
Risk to Business Strategy Execution from Recruitment Difficulties and Talent Outflows
2026-06-23
FY2026 Consolidated Revenue Growth, Operating Profit Decline and Bottom-Line Growth
2026-06-23
Revenue and profit growth in the wholesale business for prescription drugs and other products in FY2026
2026-06-23
FY2026 Self-Medication Wholesale Business: Higher Revenue and Profit
2026-06-23
FY2026 Pharmaceuticals and Related Products Manufacturing Business: Lower Revenue and Profit
2026-06-23
Revenue growth and lower operating profit in the dispensing pharmacy and related businesses for FY2026
2026-06-23
FY2026 Operating Loss in Other Businesses
2026-06-23
FY2026 Expansion in Positive Cash Flow from Operating Activities
2026-06-23
Reduction in the deficit in cash flows from investing activities for FY2026
2026-06-23
Narrower Deficit in Cash Flows from Financing Activities in FY2026
2026-06-23
FY2026 Increase in Total Assets, Liabilities and Net Assets
2026-06-23
FY2026 Total Capital Investment of ¥33.039 Billion
2026-06-23
FY2026 Research and Development Expenses of ¥2.326 Billion
2026-06-23
FY2026 Consolidated Employee Count: 12,525
2026-06-01
Expansion of the Health and Medical-Related Business
2026-06-01
Participation in the ASAGI Labs Longevity Consortium
2026-05-27
Expansion of Business Scale and Earnings Base Through Business Combinations
2026-05-20
Information Security Measures Based on Uniform Group Standards
2026-05-20
Establishment of ゲッカワークス and pilot testing of “ドクシル,” a web service for physicians
2026-05-15
Joint research with Hiroshima University Hospital on diagnostic technologies for emerging infectious diseases
2026-04-28
Differentiation through exclusive products and consultative sales
2026-04-01
Realizing higher-value-added intermediary distribution functions
2025-11-11
Operating Cash Flow Turns Positive
2025-11-11
Reform of Sales Functions and Qualification as a Medical Management Specialist
2025-11-11
FY2021-Q3 Recognition of a Provision for Losses Related to the Antimonopoly Act
2025-11-11
FY2026-H1 Consolidated Revenue and Profit Growth, but Lower Bottom-Line Profit
2025-11-11
Revenue and profit growth in the wholesale business for prescription drugs and other products in the first half of FY2026
2025-11-11
Revenue and profit growth in the self-medication wholesale business in 1H FY2026
2025-11-11
FY2026-H1: Revenue Decline and Shift to Operating Loss in Pharmaceutical and Related Products Manufacturing Business
2025-11-11
FY2026-H1 Dispensing Pharmacy and Related Businesses: Lower Revenue and Profit
2025-11-11
FY2026-H1 Operating Loss in Other Businesses
2025-11-11
FY2026-H1 Increase in Total Assets
2025-11-11
FY2026-H1 Increase in Current Assets, Accounts Receivable, Securities and Inventories
2025-11-11
FY2026-H1 Increase in Non-Current Assets
2025-11-11
FY2026-H1 Increase in Liabilities and Accounts Payable
2025-11-11
FY2026-H1 Increase in Net Assets
2025-11-11
FY2026-H1 Widening of Negative Cash Flow from Investing Activities
2025-11-11
FY2026-H1 Smaller Deficit in Cash Flow from Financing Activities
2025-11-11
FY2026-H1 R&D expenses ¥1.27 billion
2025-06-24
Transforming the Business Model Ahead of Changes in the Operating Environment
2025-06-24
Development of logistics hubs and improved logistics efficiency
2025-06-24
Entry into transportation management services for regenerative medicine products
2025-06-24
Risk of an on-site inspection by the Japan Fair Trade Commission over suspected violations of the Antimonopoly Act
2025-06-24
Sustainable Growth Based on Eight Material Issues (Materialities)
2025-06-24
Capital and business alliance with ドーナッツロボティクス
2025-06-24
Consolidated Performance, Investment and Shareholder Return Targets for the Fiscal Year Ending March 2025
2025-06-24
Consolidated performance, investment and shareholder return targets for the fiscal year ending March 2028
2025-06-24
Group-wide rollout of Health and Productivity Management Outstanding Organization certification
2025-06-24
FY2025 Consolidated Revenue Growth, Operating Profit Decline, Ordinary Profit Growth and Net Profit Decline
2025-06-24
Revenue growth and operating profit decline in the FY2025 wholesale business for prescription pharmaceuticals and related products
2025-06-24
Revenue and profit growth in the FY2025 self-medication wholesale business
2025-06-24
FY2025 Increase in Revenue and Decline in Operating Profit in the Pharmaceutical and Related Products Manufacturing Business
2025-06-24
FY2025 Medical-Related Business: Revenue Growth and Operating Profit Decline
2025-06-24
FY2025 Reduction in Positive Cash Flow from Operating Activities
2025-06-24
FY2025 expansion of the deficit in cash flow from investing activities
2025-06-24
FY2025 Expansion of the Deficit in Cash Flows from Financing Activities
2025-06-24
FY2025 Decline in Total Assets and Liabilities and Increase in Net Assets
2025-06-24
Total capital expenditures for FY2025: ¥16.466 billion
2025-06-24
FY2025 R&D Expenses: ¥1,896 Million
2025-06-24
FY2025 Consolidated Employee Headcount: 12,452
2024-11-12
Guarantee obligations for companies other than consolidated subsidiaries
2024-11-12
Participation in the Distribution System for COVID-19 Vaccines
2024-11-12
22-24 Medium-Term Management Plan "Leap into the Future"
2024-11-12
Application of Accounting Standards for Corporate Taxes, Inhabitant Taxes and Enterprise Taxes, etc.
2024-11-12
FY2025-H1 Consolidated Revenue Growth, Operating Profit Decline and Net Income Growth
2024-11-12
FY2025-H1 Revenue Growth and Lower Operating Profit in the Wholesale Business for Prescription Pharmaceuticals and Other Products
2024-11-12
FY2025 H1 Self-Medication Wholesale Business: Lower Revenue, Higher Operating Profit
2024-11-12
Higher Revenue and Operating Profit in the FY2025-H1 Pharmaceuticals and Other Products Manufacturing Business
2024-11-12
Revenue growth and decline in operating profit in the medical-related business in FY2025 H1
2024-11-12
Increase in Total Assets, FY2025-H1
2024-11-12
FY2025-H1 Increase in Current Assets and Accounts Receivable and Inventories
2024-11-12
FY2025-H1 Increase in Fixed Assets, Logistics Equipment and Investment Securities
2024-11-12
Increase in Liabilities in FY2025-H1
2024-11-12
FY2025-H1 Increase in Current Liabilities and Accounts Payable
2024-11-12
Increase in non-current liabilities in H1 FY2025
2024-11-12
FY2025-H1 Increase in Net Assets
2024-11-12
FY2025-H1 Contraction in Positive Cash Flow from Operating Activities
2024-11-12
Narrowing of the deficit in cash flows from investing activities in FY2025-H1
2024-11-12
FY2025-H1 Narrowing of the Deficit in Cash Flow from Financing Activities
2024-11-12
FY2025-H1 R&D expenses: ¥899 million
2024-06-26
Licensing and Regulatory Risks under the Pharmaceuticals and Medical Devices Act and Other Laws
2024-06-26
Risk of Customer and Confidential Information Leaks
2024-06-26
Political and Foreign-Exchange Risks Associated with China Production Facilities and Overseas Transactions
2024-06-26
Customer Credit Deterioration and Bad-Debt Risk
2024-06-26
Optimizing Group Cash Through a Cash Management System
2024-06-26
Change to the Straight-Line Method of Depreciating Property, Plant and Equipment
2024-06-26
Introduction of a performance-linked share compensation plan
2024-06-26
Maintaining a Stable Supply of Pharmaceuticals and Preventing the Spread of COVID-19
2024-06-26
Climate Change Risk Management and Information Disclosure by the TCFD Subcommittee
2024-06-26
Climate Change Risks Based on 1.5°C and 4°C Scenarios
2024-06-26
Social Bond Financing for Logistics and Pharmaceutical Manufacturing Capital Investment
2024-06-26
FY2024 Consolidated Results: Higher Revenue and Profit
2024-06-26
Revenue and profit growth in the FY2024 wholesale business for prescription drugs and other products
2024-06-26
Revenue and profit growth in the FY2024 self-medication wholesale business
2024-06-26
FY2024 Pharmaceutical and Related Products Manufacturing Business: Higher Revenue and Operating Profit
2024-06-26
FY2024: Higher revenue and profit in the healthcare-related business
2024-06-26
FY2024 Expansion of Positive Cash Flow from Operating Activities
2024-06-26
Narrowing deficit in cash flow from investing activities in FY2024
2024-06-26
FY2024 Expansion of the Deficit in Cash Flow from Financing Activities
2024-06-26
FY2024 Changes in Total Assets, Liabilities and Net Assets
2024-06-26
Total capital investment for FY2024: ¥26.759 billion
2024-06-26
FY2024 R&D Expenses: ¥2.202 Billion
2024-06-26
FY2024 Consolidated Employee Count: 12,517
2024-02-14
FY2024-Q3 Consolidated Revenue and Profit Growth
2024-02-14
Revenue and profit growth in the prescription drug and related products wholesale business in FY2024-Q3
2024-02-14
Revenue and profit growth in the self-medication wholesale business in FY2024 Q3
2024-02-14
FY2024-Q3 Revenue and Profit Growth in the Pharmaceuticals and Related Products Manufacturing Business
2024-02-14
Revenue and profit growth in the healthcare-related business in FY2024-Q3
2024-02-14
Increase in Total Assets in FY2024-Q3
2024-02-14
FY2024-Q3 Increase in Current Assets, Accounts Receivable and Inventories
2024-02-14
FY2024-Q3 Increase in Fixed Assets, Logistics Facilities and Investment Securities
2024-02-14
FY2024-Q3 Increase in Liabilities, Accounts Payable and Bonds
2024-02-14
FY2024-Q3 Decrease in Net Assets
2024-02-14
FY2024-Q3 R&D expenses of ¥1.73 billion
2023-11-10
Risk of higher labor and logistics costs due to declining inbound demand and labor shortages
2023-11-10
Risk of Restrictions on Medical Demand and Sales Activities Due to COVID-19
2023-11-10
Consolidated Higher Sales and Profits in FY2024-Q2
2023-11-10
Revenue and profit growth in the FY2024-Q2 wholesale business for prescription drugs and other products
2023-11-10
FY2024-Q2 Self-Medication Wholesale Business: Higher Revenue and Profit
2023-11-10
FY2024-Q2 Revenue Growth and Operating Profit Decline in the Pharmaceutical Products Manufacturing Business
2023-11-10
Revenue and profit growth in the medical-related business, FY2024 Q2
2023-11-10
Increase in Total Assets in FY2024-Q2
2023-11-10
FY2024-Q2 Increase in Current Assets and Accounts Receivable
2023-11-10
Increase in Fixed Assets, Capital Investment and Investment Securities in FY2024-Q2
2023-11-10
Increase in liabilities in FY2024-Q2
2023-11-10
FY2024-Q2 Increase in Current Liabilities, Accounts Payable and Short-Term Borrowings
2023-11-10
Increase in Non-Current Liabilities in FY2024-Q2
2023-11-10
FY2024-Q2 Decrease in Net Assets
2023-11-10
FY2024-Q2 Reduction in the deficit from investing activities
2023-11-10
FY2024-Q2 Widening Deficit in Cash Flow from Financing Activities
2023-11-10
FY2024-Q2 R&D Expenses: ¥1.338 Billion
2023-08-10
Higher Revenue and Earnings in FY2024-Q1
2023-08-10
FY2024-Q1 Revenue and Profit Growth in the Wholesale Business for Prescription Pharmaceuticals and Other Products
2023-08-10
Revenue and profit growth in the FY2024-Q1 self-medication wholesale business
2023-08-10
FY2024-Q1 Pharmaceutical and Related Products Manufacturing Business: Higher Sales and Shift to Operating Loss
2023-08-10
FY2024-Q1 Increase in Revenue and Return to Operating Profitability in Medical-Related Business
2023-08-10
FY2024-Q1 Increase in Total Assets
2023-08-10
Increase in current assets in FY2024-Q1
2023-08-10
FY2024-Q1 Increase in Non-current Assets
2023-08-10
FY2024 Q1 Increase in Liabilities
2023-08-10
FY2024-Q1 Increase in Current Liabilities and Accounts Payable
2023-08-10
Increase in Non-Current Liabilities, FY2024 Q1
2023-08-10
Net Asset Decline in FY2024-Q1
2023-08-10
FY2024 Q1 R&D Expenses: ¥904 Million
2023-06-27
Funding risk arising from a breach of financial covenants
2023-06-27
Suspected Antimonopoly Act Violation in NHO and JOHAS Bidding in Kyushu
2023-06-27
Pharmacy Operations Support Through Additional Investment in アクシスルートホールディングス
2023-06-27
FY2023 consolidated revenue growth and higher operating profit, with a decline in profit attributable to owners of the parent
2023-06-27
Revenue and profit growth in the FY2023 wholesale business for prescription drugs and other products
2023-06-27
Revenue and profit growth in the FY2023 self-medication wholesale business
2023-06-27
FY2023 Pharmaceutical and Related Products Manufacturing Business: Higher Revenue and Lower Operating Profit
2023-06-27
FY2023 Medical-Related Business: Higher Revenue and Segment Profit
2023-06-27
FY2023 Cash Flow from Investing Activities Turns Negative
2023-06-27
FY2023 Negative Cash Flow from Financing Activities
2023-06-27
FY2023 Increase in Total Assets, Liabilities and Net Assets
2023-06-27
Total capital investment for FY2023: ¥11.016 billion
2023-06-27
FY2023 R&D expenses of ¥2.09 billion
2023-02-14
Asia-Focused Overseas Business Expansion
2023-02-14
Adoption of the Revenue Recognition Standard
2023-02-14
Oversight of the Group's GDP and PMS compliance by the Distribution Quality Management Department
2023-02-14
FY2023-Q3: Revenue and profit growth, decline in profit attributable to owners of the parent
2023-02-14
Revenue and profit growth in the prescription pharmaceuticals and other products wholesale business for FY2023-Q3
2023-02-14
FY2023 Q3 Revenue Decline and Operating Profit Increase in the Self-Medication Wholesale Business
2023-02-14
FY2023-Q3 Pharmaceuticals and Other Products Manufacturing Business: Higher Revenue and Lower Operating Profit
2023-02-14
FY2023 Q3 Healthcare-Related Business Revenue Growth and Return to Operating Profitability
2023-02-14
Increase in Total Assets in FY2023-Q3
2023-02-14
FY2023-Q3 Increase in Current Assets, Accounts Receivable, and Inventories
2023-02-14
FY2023-Q3 Increase in Fixed Assets, Capital Expenditures and Investment Securities
2023-02-14
FY2023-Q3 Increase in Liabilities
2023-02-14
FY2023-Q3 Increase in Current Liabilities and Accounts Payable
2023-02-14
FY2023-Q3 Decrease in Non-Current Liabilities and Transfer of Provision for Antimonopoly Act-Related Losses
2023-02-14
FY2023-Q3 Increase in Net Assets
2023-02-14
FY2023-Q3 R&D expenses of ¥1,103 million
2022-11-14
FY2023-Q2 Revenue and Profit Growth
2022-11-14
Revenue and profit growth in the wholesale business for prescription drugs and other products, FY2023 Q2
2022-11-14
FY2023 Q2 Self-Medication Wholesale Business: Revenue Down, Operating Profit Up
2022-11-14
FY2023-Q2 Revenue Growth and Operating Profit Decline in the Pharmaceutical and Related Products Manufacturing Business
2022-11-14
Higher Revenue and Narrower Operating Loss in the FY2023-Q2 Healthcare Business
2022-11-14
Increase in Total Assets in FY2023-Q2
2022-11-14
FY2023-Q2 Increase in Current Assets and Accounts Receivable
2022-11-14
FY2023-Q2 Increase in Fixed Assets and Investment Securities
2022-11-14
FY2023-Q2 Increase in Liabilities
2022-11-14
FY2023-Q2 Increase in Current Liabilities and Accounts Payable
2022-11-14
FY2023-Q2 Decrease in Non-Current Liabilities
2022-11-14
FY2023-Q2 Increase in Net Assets
2022-11-14
FY2023-Q2 Expansion of the deficit in cash flows from investing activities
2022-11-14
FY2023-Q2 Negative Cash Flow from Financing Activities
2022-11-14
FY2023 Q2 R&D Expenses: ¥745 million
2022-08-12
19–21 Medium-Term Management Plan: “Challenge for Further Growth”
2022-08-12
Consolidated Performance and Capital Efficiency Targets for the Fiscal Year Ended March 2022
2022-08-12
Capital and Business Alliance with Frontier Field and 日病モバイル (a hospital mobile service)
2022-08-12
FY2023-Q1: Revenue Growth, Profit Decline
2022-08-12
FY2023-Q1 Prescription Drug and Other Wholesale Business: Higher Revenue, Lower Profit
2022-08-12
FY2023-Q1 Revenue Decline and Operating Profit Growth in the Self-Medication Wholesale Business
2022-08-12
FY2023-Q1 Declining Revenue and Profit in the Pharmaceutical and Related Products Manufacturing Business
2022-08-12
FY2023-Q1 Healthcare-Related Business: Revenue Growth and Narrower Operating Loss
2022-08-12
FY2023-Q1 Increase in Total Assets
2022-08-12
FY2023-Q1 Increase in Current Assets and Accounts Receivable
2022-08-12
FY2023-Q1 Increase in Fixed Assets and Investment Securities
2022-08-12
Increase in Liabilities in FY2023-Q1
2022-08-12
FY2023 Q1 Increase in Current Liabilities and Accounts Payable
2022-08-12
Decrease in non-current liabilities in FY2023-Q1
2022-08-12
FY2023-Q1 Increase in Net Assets
2022-08-12
FY2023-Q1 Research and Development Expenses: ¥391 million
2022-02-14
Study Group on Pharmaceutical Distribution with Yamato Transport
2022-02-14
Change in the presentation of information provision revenue, etc. as net sales
2022-02-14
FY2022-Q3 Revenue and Earnings Decline
2022-02-14
FY2022-Q3 Prescription Pharmaceuticals and Other Products Wholesale Business: Lower Revenue and Profit
2022-02-14
FY2022-Q3 Self-Medication Wholesale Business: Declining Sales and Profit
2022-02-14
FY2022-Q3 Pharmaceuticals and Other Manufacturing Business Posts Higher Revenue and Profit
2022-02-14
FY2022-Q3 Healthcare-Related Business: Revenue Growth and Continued Operating Loss
2022-02-14
FY2022-Q3 Increase in Total Assets
2022-02-14
FY2022-Q3 Increase in Current Assets
2022-02-14
FY2022-Q3 Decrease in Fixed Assets
2022-02-14
FY2022-Q3 Increase in Liabilities
2022-02-14
FY2022-Q3 Increase in Current Liabilities
2022-02-14
Decrease in non-current liabilities in FY2022-Q3
2022-02-14
FY2022-Q3 Net Assets Decline
2022-02-14
FY2022 Q3 R&D expenses: ¥1.055 billion
2021-11-12
Absorption merger of 茂木薬品商会 by アルフレッサ ヘルスケア
2021-11-12
Adoption of the accounting standard for fair value measurement
2021-11-12
Declines in Revenue and Profit in FY2022 Q2
2021-11-12
FY2022-Q2 Lower Revenue and Profit in the Wholesale Business for Prescription Pharmaceuticals and Other Products
2021-11-12
FY2022-Q2 Self-Medication Wholesale Business: Lower Revenue and Profit
2021-11-12
FY2022-Q2 Revenue and Profit Growth in the Pharmaceuticals and Related Products Manufacturing Business
2021-11-12
FY2022-Q2: Medical-related business revenue growth and continued operating loss
2021-11-12
Increase in Total Assets in FY2022-Q2
2021-11-12
FY2022-Q2 Increase in Current Assets
2021-11-12
FY2022-Q2 Decrease in Fixed Assets
2021-11-12
FY2022-Q2 Increase in Liabilities
2021-11-12
FY2022-Q2 Increase in Net Assets
2021-11-12
FY2022-Q2 Negative Cash Flow from Investing Activities
2021-11-12
FY2022-Q2 Negative Cash Flow from Financing Activities
2021-11-12
FY2022 Q2 R&D Expenses: ¥691 Million
2021-08-13
Lower revenue and profit in FY2022-Q1
2021-08-13
Lower revenue and profit in the wholesale business for prescription drugs and other products in Q1 FY2022
2021-08-13
FY2022-Q1 Self-Medication Wholesale Business: Decline in Revenue and Profit
2021-08-13
FY2022 Q1: Increased Sales and Profit in the Pharmaceutical and Related Products Manufacturing Business
2021-08-13
FY2022-Q1 Medical-Related Business: Revenue Growth and Continued Operating Loss
2021-08-13
FY2022-Q1 Research and Development Expenses of ¥355 million
2021-08-13
FY2022-Q1 Increase in Total Assets
2021-08-13
Increase in current assets and accounts receivable, FY2022-Q1
2021-08-13
FY2022-Q1 Decrease in Fixed Assets and Investment Securities
2021-08-13
Increase in Liabilities and Accounts Payable in FY2022-Q1
2021-08-13
FY2022-Q1 Decline in Net Assets
2021-06-25
Investment in a Venture Developing Breast Ultrasound Diagnostic Imaging Systems
2021-06-25
FY2021 Consolidated Revenue and Earnings Decline
2021-06-25
FY2021 Revenue and Profit Decline in the Prescription Drug and Other Pharmaceutical Wholesale Business
2021-06-25
FY2021 Self-Medication Wholesale Business: Lower Revenue and Profit
2021-06-25
FY2021 Pharmaceuticals and Related Products Manufacturing Business: Revenue Decline and Shift to an Operating Loss
2021-06-25
FY2021 Healthcare-Related Business: Revenue Decline and Shift to Operating Loss
2021-06-25
FY2021 Decline in Total Assets
2021-06-25
FY2021 Decrease in Liabilities
2021-06-25
FY2021 Increase in Net Assets
2021-06-25
FY2021 Negative Cash Flow from Investing Activities
2021-06-25
FY2021 deficit in cash flows from financing activities
2021-06-25
Total capital expenditures for FY2021: ¥25.265 billion
2021-06-25
FY2021 R&D Expenses: ¥1,438 Million
2021-02-12
Risk of recurrence of improper conduct relating to claims for dispensing fees
2021-02-12
FY2021-Q2 Contraction of the Prescription Pharmaceutical Market
2021-02-12
FY2021-Q3 Revenue and Profit Decline
2021-02-12
FY2021-Q3 Revenue and Profit Declines in the Wholesale Business for Prescription Pharmaceuticals and Other Products
2021-02-12
FY2021-Q3 Self-Medication Wholesale Business: Lower Revenue, Higher Profit
2021-02-12
FY2021-Q3 Revenue and Profit Decline in the Pharmaceuticals and Related Products Manufacturing Business
2021-02-12
FY2021-Q3 Healthcare-Related Business: Revenue Decline and Move into Operating Loss
2021-02-12
FY2021-Q3 Increase in Total Assets
2021-02-12
FY2021-Q3 Increase in Current Assets and Increases in Accounts Receivable and Inventories
2021-02-12
FY2021-Q3 Increase in Fixed Assets
2021-02-12
FY2021-Q3 Increase in Liabilities and Accounts Payable
2021-02-12
FY2021-Q3 Increase in Net Assets
2021-02-12
FY2021-Q3 Research and Development Expenses of ¥1,065 million
2020-11-12
FY2021 Q2: Lower Revenue and Profit
2020-11-12
Revenue and profit decline in the medical pharmaceuticals and other wholesale business in FY2021 Q2
2020-11-12
FY2021-Q2 Self-Medication Wholesale Business: Revenue Decline, Profit Growth
2020-11-12
FY2021-Q2 Pharmaceuticals and Related Manufacturing Business: Lower Revenue and Profit
2020-11-12
FY2021 Q2 Medical-Related Businesses: Revenue Decline and Shift into Operating Loss
2020-11-12
Decrease in total assets in FY2021-Q2
2020-11-12
FY2021-Q2 Decrease in Current Assets and Increase in Fixed Assets
2020-11-12
FY2021-Q2 Liabilities Decrease
2020-11-12
FY2021-Q2 Increase in Net Assets
2020-11-12
FY2021-Q2 Negative Cash Flow from Investing Activities
2020-11-12
FY2021-Q2 R&D expenses: ¥659 million
2020-08-07
FY2021-Q1 Revenue and Earnings Decline
2020-08-07
FY2021-Q1: Lower Revenue and Profit in the Wholesale Business for Prescription Pharmaceuticals and Other Products
2020-08-07
FY2021-Q1 Self-Medication Wholesale Business: Revenue Down, Profit Up
2020-08-07
FY2021-Q1 Revenue Decline and Shift to Operating Loss in the Pharmaceutical and Related Products Manufacturing Business
2020-08-07
FY2021-Q1 Healthcare-Related Business: Decline in Revenue and Shift to an Operating Loss
2020-08-07
FY2021-Q1 Increase in Total Assets
2020-08-07
FY2021-Q1 Cash Decrease, Accounts Receivable Increase and Investment Securities Increase
2020-08-07
FY2021-Q1 Increase in Liabilities and Accounts Payable
2020-08-07
FY2021-Q1 Increase in Net Assets
2020-08-07
FY2021-Q1 Research and Development Expenses: ¥321 million
2020-02-14
FY2020-Q3: Revenue Up, Profit Down
2020-02-14
3.7% Growth in the FY2020-Q3 Prescription Drug Market
2020-02-14
FY2020-Q3 Wholesale Business for Prescription Pharmaceuticals and Other Products: Higher Revenue, Lower Profit
2020-02-14
FY2020-Q3 Revenue Growth and Profit Decline in the Self-Medication Wholesale Business
2020-02-14
FY2020-Q3 Pharmaceutical and Related Products Manufacturing Business: Higher Revenue and Profit
2020-02-14
Revenue and profit growth in the medical-related business in FY2020 Q3
2020-02-14
FY2020-Q3 Increase in Total Assets
2020-02-14
FY2020-Q3 Increase in Accounts Receivable and Inventory, and Decrease in Cash
2020-02-14
FY2020-Q3 Increase in Liabilities and Accounts Payable
2020-02-14
Increase in Net Assets in FY2020-Q3
2019-11-13
FY2020-Q2 Revenue and Profit Growth
2019-11-13
4.9% Growth in the Prescription Drug Market in Q2 FY2020
2019-11-13
Revenue and profit growth in the prescription pharmaceuticals and other wholesale business in FY2020 Q2
2019-11-13
Revenue Growth and Profit Decline in the FY2020-Q2 Self-Medication Wholesale Business
2019-11-13
FY2020-Q2 Revenue and Profit Growth in the Pharmaceutical and Other Products Manufacturing Business
2019-11-13
Medical-related business: revenue growth and return to operating profitability in FY2020 Q2
2019-11-13
FY2020 Q2: ¥11.263 billion spent on acquisition of property, plant and equipment
2019-08-09
FY2020-Q1 Revenue Growth and Profit Decline
2019-08-09
0.7% Growth in the FY2020-Q1 Prescription Drug Market
2019-08-09
FY2020 Q1: Higher Revenue, Lower Profit in the Wholesale Business for Prescription Pharmaceuticals and Related Products
2019-08-09
FY2020-Q1 Revenue and Profit Declines in the Self-Medication Wholesale Business
2019-08-09
FY2020-Q1 Pharmaceuticals and Related Products Manufacturing Business: Higher Revenue and Profit
2019-08-09
FY2020-Q1: Revenue growth and return to operating profitability in the Medical Business
2019-06-26
16-18 Medium-Term Management Plan: Progress Toward Tomorrow
2019-06-26
Improving Pharmaceutical Delivery Productivity with saios
2019-06-26
Strategic partnership with China Resources Pharmaceutical Commercial Group in the Chinese pharmaceutical distribution business
2019-06-26
FY2019 Consolidated Higher Revenue and Profits
2019-06-26
Revenue and profit growth in the FY2019 wholesale business for prescription drugs and other products
2019-06-26
Revenue and profit growth in the FY2019 self-medication wholesale business
2019-06-26
FY2019 Pharmaceutical and Related Products Manufacturing Business: Lower Revenue and Lower Profit
2019-06-26
FY2019 Medical-Related Business: Revenue Up, Profit Down
2019-06-26
FY2019 Operating Cash Flow Remains Positive
2019-06-26
FY2019 Total Capital Investment: ¥15.195 billion
2019-02-12
FY2019 Q3: Higher Revenue and Profit
2019-02-12
Revenue and profit growth in the ethical pharmaceuticals and other wholesale business, FY2019 Q3
2019-02-12
Revenue and profit growth in the self-medication wholesale business, FY2019 Q3
2019-02-12
FY2019-Q3 Pharmaceutical Products Manufacturing Business: Lower Revenue and Profit
2019-02-12
FY2019-Q3: Revenue increased and operating profit decreased in the Medical-Related Business
2018-11-09
FY2019 Q2: Higher Revenue and Profit
2018-11-09
Higher Revenue and Profit in the FY2019 Q2 Wholesale Business for Prescription Pharmaceuticals and Other Products
2018-11-09
FY2019-Q2 Self-Medication Wholesale Business: Higher Revenue, Lower Profit
2018-11-09
FY2019-Q2 Decline in Revenue and Operating Profit in the Pharmaceuticals and Related Products Manufacturing Business
2018-11-09
FY2019-Q2: Revenue Growth and Shift to an Operating Loss in the Medical-Related Business
2018-08-10
FY2019 Q1: Higher Revenue and Profit
2018-08-10
FY2019 Q1: Higher Revenue and Profit in the Wholesale Business for Prescription Pharmaceuticals and Other Products
2018-08-10
Revenue and profit growth in the self-medication wholesale business, FY2019 Q1
2018-08-10
FY2019 Q1: Lower Revenue and Profit in the Pharmaceuticals and Other Products Manufacturing Business
2018-08-10
FY2019-Q1 Medical-Related Business: Higher Revenue and Shift to an Operating Loss
2018-02-13
Expansion of Joint Use of the Group's Core System
2018-02-13
Communicating Sustainability Management through an Integrated Report
2018-02-13
FY2018 Q3: Higher Revenue and Profit
2018-02-13
Higher Revenue and Profit in the FY2018 Q3 Wholesale Business for Prescription Pharmaceuticals and Other Products
2018-02-13
Revenue and profit growth in the self-medication wholesale business, FY2018 Q3
2018-02-13
FY2018-Q3 Revenue and Operating Profit Growth in the Pharmaceuticals and Related Products Manufacturing Business
2018-02-13
Revenue and profit growth in the Medical-Related Business for FY2018 Q3
2017-11-10
FY2018 Q2: Higher Revenue and Profit
2017-11-10
Revenue and profit growth in the wholesale business for prescription drugs and other products, FY2018 Q2
2017-11-10
Revenue and profit growth in the self-medication wholesale business in FY2018 Q2
2017-11-10
FY2018 Q2: Higher Revenue and Profit in the Pharmaceuticals and Other Products Manufacturing Business
2017-11-10
FY2018-Q2 Medical-Related Business: Higher Revenue and Profit
2017-08-10
FY2018-Q1: Higher Revenue, Lower Profit
2017-08-10
Lower revenue and profit in the wholesale business for prescription drugs and other products in FY2018-Q1
2017-08-10
Revenue and profit growth in the FY2018-Q1 self-medication wholesale business
2017-08-10
FY2018 Q1 Revenue and Profit Growth in the Pharmaceutical and Related Manufacturing Business
2017-08-10
FY2018-Q1 Revenue Growth and Return to Operating Profitability in the Medical-Related Business
2017-02-10
FY2017-Q3 Revenue and Earnings Decline
2017-02-10
FY2017-Q3 Revenue and profit decline in the prescription pharmaceuticals and related products wholesale business
2017-02-10
Revenue and profit growth in the self-medication wholesale business, FY2017 Q3
2017-02-10
Revenue and profit growth in the pharmaceuticals and related products manufacturing business in Q3 of FY2017
2017-02-10
FY2017-Q3 Healthcare-Related Business: Lower Revenue and Operating Profit
2016-11-11
FY2017-Q2 Revenue and Earnings Decline
2016-11-11
Lower revenue and earnings in the wholesale business for prescription drugs and other pharmaceuticals
2016-11-11
Revenue and profit growth in the self-medication wholesale business
2016-11-11
Higher revenue and profit in the pharmaceuticals and related products manufacturing business
2016-11-11
Healthcare-Related Business: Higher Revenue, Lower Profit
2016-08-10
Revenue and earnings growth in FY2017-Q1
2026-08-10
Declining Revenue and Earnings and Sales Volumes Below Plan
2026-08-10
Borrowings Subject to Financial Covenants
2026-08-10
Issuance of Stock Acquisition Rights
2026-08-10
Operating Cash Outflows Associated with Higher Inventories
2026-08-10
Higher Short-Term Borrowings and Liabilities and a Lower Equity Ratio
2026-08-10
Higher Total Assets Due to Increases in Cash and Trade Receivables
2026-08-10
Increase in Retained Earnings Due to Changes in the Scope of Consolidation
2026-08-10
Risk of Foreign Exchange Losses From Increased Foreign-Currency Settlements
2026-08-10
Risk of Overseas Customers' Bankruptcy, Payment Delays and Fraud
2026-08-10
Additional Working Capital Funding Capacity Through Expanded Overdraft Facilities
2026-08-10
Decline in Domestic Used-Vehicle Registrations and Increase in Used-Vehicle Exports
2026-08-10
Recognition of Store-Closure Losses
2026-08-10
Decrease in Comprehensive Income Due to the Share of Earnings of Equity-Method Affiliates
2026-08-10
Liquidity Risk From Rapid Sales Growth and Increases in Trade Receivables and Inventories
2026-08-10
Risk of Changes in the Recoverability of Deferred Tax Assets
2026-08-10
Higher Used-Vehicle Market Prices and Gross Profit per Vehicle Due to Lower New-Vehicle Production
2026-08-10
Disclosure of Revenue by Transaction Type, Including Vehicle, Auction and Franchise Sales
2026-08-10
Increase in non-controlling interests
2026-08-10
Increase in the Foreign Currency Translation Adjustment
2026-08-10
Entry into the Branded-Goods Purchasing Business for Watches and Precious Metals
2026-08-10
Sustainability Policy Focused on Harmony With Society and the Global Environment
2026-08-10
Addressing Global Environmental Issues Through Used-Vehicle Distribution
2026-08-10
Financial Services Agency Sanctions Against Asuka Audit Corporation and Ensuring the Reliability of the Audit Structure
2026-08-10
Risk From Increasing Chinese-Made Electric Vehicles in Sales of Japanese-Made Vehicles to Thailand
2026-08-10
Recognition of Reversal Gain on Provision for Directors' Retirement Benefits
2026-08-10
Recognition of Compensation Income
2026-08-10
Retirement of an Outside Director and the Composition of the Board
2026-05-07
Strengthening Internal Controls and Corporate Governance
2025-08-08
Streamlining the Group Structure Through the Sale and Liquidation of Affiliates
2025-03-28
Emphasis on Revenue Growth, Ordinary Profit Margin and Return on Equity
2025-03-28
Recruiting and Developing Talent and Introducing Job Rotation and Incentives
2025-03-28
Higher Revenue in Japan and Lower Revenue in Asia
2025-03-28
Risk of Inventory Write-Downs Due to Market Conditions and Falling Selling Prices
2025-03-28
Hedging Interest Rates on Long-Term Borrowings Through Interest-Rate Swaps
2025-03-28
Investing Cash Outflows From Loans Extended
2025-03-28
Policy for Determining Individual Director Compensation and Performance-Based Compensation
2025-03-28
Growth in the Business Performance of Apple Auto Auction (Thailand) Company Limited
2025-03-28
Preventing Corruption, Respecting Human Rights and Eliminating Child and Forced Labor
2025-03-28
Board Deliberation and Oversight of Sustainability Activities
2025-03-28
No Specific Sustainability Targets Established
2025-03-28
Requesting Business Partners to Follow the Sustainability Policy and Stakeholder-Specific Codes of Conduct
2025-03-28
Risk of Difficulty Securing Reusable Goods Due to Economic Conditions, Competition and Changes in Consumer Sentiment
2025-03-28
Diversification of Procurement Channels for Reusable Goods Through Delivery, In-Store and In-Home Purchasing
2024-03-29
Funding Costs for New-Vehicle Purchases in China and Deteriorating Profitability
2024-03-29
Expanding Purchases and Export Channels for Used Commercial Vehicles Manufactured by ISUZU MOTORS LIMITED
2024-03-29
Strengthening the Organization Through the Visionary Company Slogan
2024-03-29
Globalization and Digitalization of the Used-Vehicle Business
2024-03-29
Achieving the No. 1 Customer Satisfaction Ranking and Japan's No. 1 Chain
2024-03-29
The Expansion-with-Balance Policy: Balancing Existing-Business Earnings with New-Business Investment
2024-03-29
Assessing the Profitability of New Businesses Through Market Research and Information Sharing
2024-03-29
Establishing Management and Organizational Structures Appropriate to the Business Scale
2024-03-29
Dependence on Dealers and Other Suppliers and the Risk of Procurement Disruptions
2024-03-29
Risk of Changes in Import Regulations Affecting Used-Vehicle Exports to Southeast Asia
2024-03-29
Risk of Intensifying Competition in Used-Vehicle Exports to Southeast Asia
2024-03-29
Risk of Higher Ocean Freight Rates
2024-03-29
Delivery Delays and Inventory Buildup Due to Shortages of Vehicle Carrier Capacity and Bad Weather
2024-03-29
Country Risk From Political and Economic Changes in Southeast Asia
2024-03-29
Risk of Intensifying Competition in the Domestic Used-Vehicle Purchasing Business
2024-03-29
Risk of Claims Arising From Defects in Used Vehicles Sold
2024-03-29
Brand and Performance Risks From Franchisee Misconduct, Contract Terminations and Closures
2024-03-29
Risk of Reduced Business Activity Due to Natural Disasters and Fires
2024-03-29
Risk of Legal Liability and Loss of Credibility Due to Personal Information Leaks
2024-03-29
Risk of Brand-Value Damage From Trademark Imitation
2024-03-29
Future Application of the Accounting Standards for Tax Effect Accounting and Revenue Recognition
2024-03-29
Exclusive Japanese Distribution Agreement for Electric Vehicles
2024-03-29
Becoming a General Trading Company in the Automotive Distribution Market
2024-03-29
Concentration of Sales Among Major Overseas Customers
2024-03-29
Recognition of Impairment Loss on Shares of Affiliates
2024-03-29
Risk of Difficulty Securing Talent Due to Intensifying Competition for Human Resources
2024-03-29
Risk of Changes in Demand Due to Reduced Interest in Car Ownership, Longer Holding Periods and Car Sharing
2024-03-29
Recognition of Insurance Proceeds
2023-11-10
Improving Capital Efficiency and Enabling Flexible Capital Policies Through the Repurchase of Shares Held by ISUZU MOTORS LIMITED
2023-11-10
Recognition of Losses on Sales of Non-Current Assets
2023-08-10
Assumption That the Impact of COVID-19 Would Gradually Ease During the Fiscal Year Ending December 2020
2023-08-10
Recognition of Losses From Theft
2023-05-12
Recognition of Gain on Sale of Shares in Beijing Affiliates
2023-03-27
Raising Growth Capital Through a Third-Party Allotment to ISUZU MOTORS LIMITED
2023-03-27
Impairment Risk for Fixed and Leased Assets
2023-03-27
Infection-Control Measures and Establishment of Sales Operations and Work Styles Using Online Meetings
2022-05-13
Planned Application of the Accounting Standard for Fair Value Measurement
2022-03-28
Recognition of Provision Expense for Losses on Affiliates' Businesses
2022-03-28
Cost Reduction in Selling, General and Administrative Expenses
2022-03-28
Higher Automotive Demand Driven by Southeast Asian Events and Special Tax and Economic-Stimulus Policies
2022-03-28
Expansion of New-Vehicle Sales and Maintenance Through the Acquisition of Honda Shop Hinaga Co., Ltd.
2022-03-28
Application of the Accounting Standard for Disclosure of Accounting Estimates
2021-03-29
Expansion of New-Vehicle Sales and Maintenance Through the Acquisition of Garage East Japan Co., Ltd.
2020-11-13
Three-Consecutive-Period Condition of Consolidated Operating Profit of at Least ¥700 Million
2020-03-30
Concentration of Management Resources on the Domestic Japanese Business
2019-11-08
Application of Accounting Treatment for Paid Stock Acquisition Rights with Vesting Conditions
2018-11-08
Offsetting Deficits and Improving Financial Strength Through a Capital Reduction and Disposal of Surplus
2018-11-08
Expected Realization Gain on Foreign Currency Translation Adjustments Upon AIH Liquidation
2018-03-23
Entry into the Car-Leasing Business, Apple Lease
2026-10-13
Dividend Payment to Shareholders (¥10 per Share)
2026-10-13
Single-Segment Structure Focused on the Restaurant Business
2026-10-13
Challenging dining-out demand conditions due to sluggish personal consumption
2026-10-13
Strengthening the Product Appeal of Core Japanese Dishes
2026-10-13
Interest Rate Risk Associated with Interest-Bearing Debt and Variable Rates
2026-10-13
Funding New Store Openings with Cash Flows from Operating Activities
2026-10-13
Strengthening Financial Soundness Amid the COVID-19 Pandemic
2026-10-13
Stabilizing the cost ratio in response to soaring procurement prices
2026-10-13
Sales Promotion Through Flyers and Leaflet Distribution, and Effectiveness Measurement
2026-10-13
Recognition of ¥25.098 million in compensation received
2026-10-13
Systematizing Store Operations for Multi-Store Expansion
2026-10-13
Strengthening reservation support and Japanese cuisine services for international visitors to Japan through a dedicated department
2026-10-13
Mobile Ordering Rolled Out Across All Stores and Digitization of Store Operations
2026-10-13
Establishment of an Executive Retirement Benefit System
2026-10-13
Recognition of ¥81.9 million in executive retirement benefits
2026-10-05
Impact on overall sales from declining sales at existing stores
2026-10-05
Increase in Average Sales per Store
2026-10-05
Downward Revision to the Full-Year Consolidated Earnings Forecast for the Fiscal Year Ending February 2027
2026-05-29
Opening of the まるまつ Misawa Store and Contribution to Sales
2026-05-29
New まるまつ Japanese-Style Restaurant Opening
2026-05-29
Store portfolio centered on “まるまつ”
2026-05-29
Securing and Developing Human Resources
2026-05-29
Long-term targets of 1,000 stores, ¥100 billion in sales and ¥10 billion in ordinary profit
2026-05-29
Low-price business format with an average customer spend of around ¥800
2026-05-29
Introduction of an Elective Defined Contribution Pension Plan
2026-05-29
Compliance Management Through Internal Audit and Whistleblower Protection
2026-05-29
Decrease in the Number of Temporary Employees Due to COVID-19
2026-05-29
Independent, Objective Oversight Framework Involving Outside Officers
2026-05-29
Appointment of a temporary audit & supervisory board member following the resignation of an outside audit & supervisory board member
2026-05-29
Energy efficiency, CO2 reduction and EV charger installation
2026-05-29
Human Capital Metrics on Women’s Advancement and Balancing Work and Childcare
2026-05-29
Application of Lease-Related Accounting Standards and Related Guidance from the Beginning of the Fiscal Year Ending February 2029
2026-05-29
Initial application at the beginning of the fiscal year ending February 2029 of accounting standards and related requirements concerning subsequent events
2026-05-29
Change in the Representative Director and President
2026-05-01
Strengthening Governance to Enhance Corporate Value and Transparency
2026-04-06
Strengthening service capabilities to create a comfortable dining environment
2026-04-06
Building an integrated system from production to sales (mass merchandising)
2026-04-06
Dividend forecast for the next period: Undecided
2025-10-14
Impact of Food Safety and Hygiene Issues on Business Performance
2025-10-14
Creating revenue opportunities by expanding products sold in stores
2025-10-14
Application of Standards Concerning Income Taxes, Comprehensive Income and Tax-Effect Accounting
2024-10-11
Recognition of Store Closure Losses
2024-10-11
Customer First and Achieving Customer Satisfaction
2024-10-11
Issuing Employee Stock Options
2024-07-12
Stabilizing cash on hand and the financial foundation through a subordinated loan with equity-like characteristics
2024-05-24
Basic Policy of Offering Healthy, Delicious Meals at Value Prices
2024-05-24
Contributing to Society Through Food Service
2024-05-24
Introduction of HACCP at the Main Plant
2024-05-24
Cost reductions across stores, logistics, factories and headquarters
2024-05-24
Impact of Labor Shortages on Store Opening Plans and Business Performance
2024-05-24
Intensifying Competition with Food-Service, Prepared-Meal and Delivery Operators
2024-05-24
Store-opening risks from mismatched opening conditions and changes in the location environment
2024-05-24
Risks Relating to the Recovery of Security Deposits and Guarantee Deposits and Early Termination of Store Leases
2024-05-24
Concentration of Logistics and Production Functions in Tomiya, Miyagi Prefecture
2024-05-24
Additional Costs from Tighter Regulations Related to Food Service
2024-05-24
Litigation Risk
2024-05-24
Stable Profit Returns and Enhancement of Retained Earnings
2024-05-24
Building a dominant store network in Tohoku and Northern Kanto
2024-05-24
New Format Development
2024-05-24
Improving the Lives of Working People
2024-05-24
Meal Voucher Benefits for Shareholders
2024-05-24
Restrictions on going out, economic stagnation and downward pressure on sales caused by the spread of COVID-19
2024-05-24
¥1.3 Billion Borrowing as a Precaution Against COVID-19
2024-05-24
Cross-Shareholdings Held for Medium- to Long-Term Business Relationships
2024-05-24
亘理ファーム’s consolidation as a consolidated subsidiary
2024-05-24
Borrowings Subject to Financial Covenants
2024-05-24
Risk Management Through an Emergency Response Manual for Disasters
2024-05-24
Target of Keeping the Food Loss Rate at or Below 0.2%
2024-05-24
Women to account for at least 20% of management positions by the end of March 2028
2024-05-24
Acquisition of 243,000 Treasury Shares
2024-01-12
Accounting Estimates Based on Assumptions Regarding the Impact of COVID-19
2024-01-12
Increase in subsidy income
2023-07-13
Improving profitability by closing unprofitable stores
2023-05-26
Future application of the accounting standard for revenue recognition
2023-05-26
Plan to Establish a New Narita Plant
2023-05-26
まるまつ’s New Points Card Program and Resumption of Member Enrollment
2023-05-26
Ensuring flexibility and agility in capital policy through reductions in stated capital and capital reserve
2023-05-26
Improving Management Resource Efficiency and Strengthening the Financial Position through the Transfer of Idle Fixed Assets
2023-01-13
Infection Prevention Measures for Customers and Employees in Response to COVID-19
2023-01-13
Developing a New Sales Channel through the Fresh Market “Fresh Marche”
2022-10-14
Recognition of income from expired points
2022-07-14
Improving Culinary Standards Through the Development and Assignment of Culinary Meisters
2022-07-14
Separate presentation of points provision
2022-07-14
Future adoption of accounting standards for fair-value measurement
2022-05-27
Concentration of management resources through the absorption-type merger of ネットワークサービス
2022-05-27
First store opening at an expressway parking area
2022-05-27
Application of the Accounting Standard for Disclosure of Accounting Estimates
2022-01-13
Recognition of income taxes adjustment from the reversal of deferred tax assets
2021-10-14
Decline in Customer Traffic Due to Changes to Business Hours
2021-07-14
Disclosure stating that the earnings forecast for the fiscal year ending February 2022 is undetermined
2021-05-28
Debt Guarantees for Borrowings by an Unconsolidated Subsidiary
2021-05-28
Change in Depreciation Method for Building Equipment and Structures
2021-05-28
Products provided within 10 minutes
2021-05-28
Store Renovations Through Format Changes
2021-05-28
Performance target management based on a medium-term management plan covering three fiscal years
2021-05-28
Loans to an Unconsolidated Subsidiary
2020-05-26
Store Development Tailored to Local Characteristics
2020-05-26
Application of Guidance on the Recoverability of Deferred Tax Assets
2020-05-26
Application of Partial Amendments to the Accounting Standard for Tax Effect Accounting
2019-10-15
Increase in customer traffic due to the 10-day holiday period
2018-01-12
Decrease in net sales due to lower average spend per customer
2017-07-14
Decline in Customer Traffic Following Menu Changes and Review of Alcohol Sales Campaigns
2017-05-25
Application of Business Combination Accounting Standards and Changes in Presentation
2017-05-25
Store expansion guided by the motto “More delicious, more enjoyable, more convenient”
2017-05-25
Strengthening the Appeal of Tonkatsu Products through the Introduction of Automatic Fryers
2026-09-17
Full-Scale Entry into the Defense Equipment Market and Establishment of Terra Defense
2026-09-17
Building a domestic supply chain for defense drones
2026-09-14
Building a global platform for the low-altitude economy
2026-09-14
A two-segment business combining hardware, software, services and UTM
2026-09-14
Growth of New and Existing Businesses Through Aggressive Investment
2026-09-14
End-to-end services from pre-flight permit approvals through flight operations management
2026-09-14
Continued investment in human capital
2026-09-14
Net sales edged up, while operating loss widened
2026-09-14
Downside Risks to the Global Economy from High Interest Rates, US-China Trade Friction and Policy Uncertainty
2026-09-14
Development of an Operations Management System for Flying Cars
2026-09-14
Expansion of Terra Xross 1 Mass Production and Overseas Sales
2026-09-14
Ranked No. 1 worldwide among drone services companies in 2024
2026-09-14
Strengthening Internal Management and Governance Systems in Response to Business Expansion
2026-09-14
Fire at an Indonesian Subsidiary, Safety Management and Litigation Risks
2026-09-14
Continuation and expansion of the agricultural business in Indonesia and Malaysia
2026-09-14
Risk of Business Disruption from Cyberattacks and Information Leaks
2026-09-14
Litigation risks arising from intellectual property infringement and service disruptions
2026-09-14
Risk of tighter drone export controls
2026-09-14
Country, Collection and Geopolitical Risks from Overseas Expansion
2026-09-14
Share Dilution From the Exercise of Stock Acquisition Rights
2026-09-14
Sustainable drone society and agricultural operations centered on ESG
2026-09-14
Initial Order for 300 Domestically Produced Drones from the Acquisition, Technology & Logistics Agency
2026-09-14
Entry into the domestic battery business for drones
2026-09-14
Strengthening Swiss and European Regulatory Support Through the Acquisition of Sora Consulting GmbH
2026-09-14
Reallocation of IPO Proceeds to Prioritize Growth Investments in Subsidiaries
2026-09-14
Raising Growth Capital Through Exercise of Stock Acquisition Rights
2026-09-14
Combination of UTM Initial Implementation Fees and Recurring Revenue
2026-09-14
Policy of Revising Full-Year Forecasts Based on Full-Year Outlook Despite Quarterly Volatility
2026-09-14
Flexible Capital Policy and Financial Strategy
2026-09-14
Reducing Subsidy Dependence in Domestic UTM and Shifting to Self-Sustaining Revenue
2026-09-14
Preparations to establish a joint venture with Besomar and announcement of the Terra C1 reconnaissance drone
2026-07-27
Risk of Surging Prices for Imported Components and Materials
2026-07-27
Mass Production and External Sales of Domestic High-Power Drone Batteries
2026-06-15
Impairment Risk from Deteriorating Performance at Acquired and Investee Companies
2026-06-15
Policy of prioritizing retained earnings and considering future dividends
2026-06-15
Structural Expansion of the Non-Chinese Drone Market
2026-06-15
Shift to and Growth of Infrastructure-Facility Businesses in Saudi Arabia
2026-04-30
Making Terra DX Solutions and EuroUSC Italia subsidiaries
2026-04-30
Expansion of the AI-powered automated transmission tower inspection system
2026-04-30
Expansion of Terra SLAM RTK for public works and BIM/CIM
2026-04-30
Achieving profitability through growth in each business
2026-04-30
Transition to Real-Time Risk and Compliance Management
2026-04-30
Declining social confidence and product liability arising from drone accidents
2026-04-30
Business Continuity Risk from Natural Disasters and Infectious Diseases
2026-04-30
Foreign-Exchange Risk Associated with Overseas Business Expansion
2026-04-30
Post-M&A integration and failure to achieve plans
2026-04-30
Product liability relating to drone crashes and laser products
2026-04-30
Business interruption and financial reporting delays caused by incidents at overseas facilities
2026-04-30
Constraints on business expansion due to insufficient recruitment and development of talent
2026-04-30
Risk of the Representative Director and President Holding a Position at Another Company
2026-04-30
Dependence on a Specific Individual and Delegation of Authority
2026-04-30
Reputational risk arising from other companies using the Terra brand
2026-04-30
Cancellation of the procedures to make Aloft Technologies a wholly owned subsidiary
2026-04-30
More Efficient and Engaging Shareholders Meetings and Clearer Management Accountability
2026-04-30
Reducing Subsidy Dependence and Strengthening Sales of Lower-Priced Domestic Hardware
2026-04-01
Strengthening disaster response and prevention through industrial drones